Drug intelligence / Profile preview

AFX-0970

Development stage: Unknown
Lead developer: Afecta Pharmaceuticals
Modality: Small Molecules
Administration: Topical

Overview

AFX-0970 is a small molecule topical therapeutic developed by Afecta Pharmaceuticals for the treatment of scarring and pigmentation disorders. According to the company's pipeline, the product is currently marketed for these dermatological indications. While the specific active ingredients and molecular targets are not publicly disclosed, the drug is part of Afecta's proprietary AFX technology platform, which focuses on optimizing the delivery and efficacy of dermatological treatments. It is intended to improve skin texture and tone by addressing hyperpigmentation and scar tissue formation.

Beyond the preview

Go deeper on AFX-0970.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AFX-0970.

Explore the full profile